Key Drivers
- Strong Liquidity
- Ongoing Cash Burn
- Extreme Leverage
AIAI Summary
BHVN is now a high-risk regulatory-resolution trade: upside depends on an intact, positive RISE3 readout and a manageable FDA hold, while prolonged safety scrutiny could trigger further delays, dilution, and a reassessment of opakalim's viability. Investors should treat the SK partnership as contingent validation—not funding certainty—and watch for FDA clarity and RISE3 timing before underwriting a rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Ongoing Cash Burn
- •Extreme Leverage
BHVN has strong near-term liquidity and improving losses, but remains a high-risk investment due to zero revenue, persistent cash burn, thin equity, and extreme leverage.
Price Behavior
Key Price Behavior Insights:
- •Recent sharp selloff
- •Fragile rebound attempt
- •Key resistance overhead
BHVN remains technically weak over the last month, with support at $12.00–$12.30 and a sustained break above $13.90–$14.00 needed to confirm a more reliable recovery.
Sharp drop from near $16.95 to $12.02 before a brief rebound
Sentiment & News
Key News Insights:
- •SK licensing deal
- •FDA clinical hold
- •Investor scrutiny
Biohaven gained licensing, legal, and institutional support, but FDA's partial hold on opakalim creates significant near-term regulatory risk.
The clinical hold is likely to outweigh earlier positive catalysts until trial timelines and safety concerns are clarified
Similar Companies in Healthcare
Other companies in the same sector with AI ratings